Patents-Review.com
🔗 Permalink
Assignee profile:

ARRAY BIOPHARMA INC.

City:

Boulder, Colorado

Country:

United States

Published Applications:

383

Last publication date:

2025-07-03

Patent Grants:

321

Last grant date:

2025-07-22

Quarterly ARRAY BIOPHARMA INC. Patent Applications

Top Inventors for applications by ARRAY BIOPHARMA INC.

These are the the leading inventors for applications assigned to ARRAY BIOPHARMA INC.:

Recent patent applications by ARRAY BIOPHARMA INC.

ARRAY BIOPHARMA INC. based in Boulder, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-07-03
US20250214966A1
Chemistry; metallurgy

Crystalline Salt Form Of A SHP2 Inhibitor

 #2 | 2025-05-15
US20250152560A1
Human necessities

HDAC INHIBITOR OKI-179 IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF CANCER

 #3 | 2025-02-27
US20250066357A1
Chemistry; metallurgy

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

 #4 | 2025-01-09
US20250011304A1
Chemistry; metallurgy

CRYSTALLINE FORM OF N-(2-CHLORO-3-((5-CHLORO-3-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)AMINO)-4-FLUOROPHENYL)-3-FLUOROAZETIDINE-1-SULFONAMIDE

 #5 | 2025-01-02 ✅ Patent 12,364,684 granted on 2025-07-22
US20250000848A1
Human necessities

PHARMACEUTICAL COMPOSITION

 #6 | 2024-12-26 ✅ Patent 12,318,367 granted on 2025-06-03
US20240423960A1
Human necessities

Pharmaceutical composition

 #7 | 2024-09-19 ✅ Patent 12,630,566 granted on 2026-05-19
US20240309020A1
Chemistry; metallurgy

KRAS G12D INHIBITORS

 #8 | 2024-06-13
US20240190843A1
Chemistry; metallurgy

CRYSTALLINE FORM OF A SHP2 INHIBITOR

 #9 | 2024-05-30
US20240174666A1
Chemistry; metallurgy

PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

 #10 | 2024-04-18
US20240124474A1
Chemistry; metallurgy

HER2 MUTATION INHIBITORS

 #11 | 2024-04-18
US20240124453A1
Chemistry; metallurgy

PROTEIN TYROSINE PHOSPHATASE INHIBITORS

 #12 | 2024-02-29 ✅ Patent 11,998,545 granted on 2024-06-04
US20240066029A1
Human necessities

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

 #13 | 2024-02-08 ✅ Patent 12,465,593 granted on 2025-11-11
US20240041835A1
Human necessities

PHARMACEUTICAL COMPOSITION

 #14 | 2024-02-08 ✅ Patent 12,220,403 granted on 2025-02-11
US20240041834A1
Human necessities

Pharmaceutical composition

 #15 | 2023-08-03
US20230241066A1
Human necessities

POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

 #16 | 2023-06-22
US20230190749A1
Human necessities

TREATMENT OF BRAIN CANCER

 #17 | 2023-05-11 ✅ Patent 12,171,739 granted on 2024-12-24
US20230142839A1
Human necessities

N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

 #18 | 2023-04-20
US20230117328A1
Human necessities

METHODS TO TREAT CANCER USING (R)-N-(3-FLUORO-4-((3-((1-HYDROXYPROPAN-2-YL)AMINO)-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)OXY)PHENYL)-3-(4-FLUOROPHENYL)-1-ISOPROPYL-2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE

 #19 | 2023-03-30
US20230097309A1
Human necessities

SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR

 #20 | 2023-03-09 ✅ Patent 11,964,989 granted on 2024-04-23
US20230077225A1
Chemistry; metallurgy

KRas G12D inhibitors

 #21 | 2023-02-09 ✅ Patent 12,447,153 granted on 2025-10-21
US20230041385A1
Human necessities

HER2 MUTATION INHIBITORS

 #22 | 2023-01-26 ✅ Patent 11,834,453 granted on 2023-12-05
US20230023851A1
Chemistry; metallurgy

Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

 #23 | 2023-01-12 ✅ Patent 11,780,835 granted on 2023-10-10
US20230011441A1
Chemistry; metallurgy

PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

 #24 | 2022-10-06 ✅ Patent 11,648,243 granted on 2023-05-16
US20220313676A1
Human necessities

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

 #25 | 2022-09-15 ✅ Patent 11,634,409 granted on 2023-04-25
US20220289721A1
Chemistry; metallurgy

Compounds for the treatment of BRAF-associated diseases and disorders

 #26 | 2022-09-15 ✅ Patent 12,303,509 granted on 2025-05-20
US20220288074A1
Human necessities

Compounds for the treatment of BRAF-associated diseases and disorders

 #27 | 2022-08-11 ✅ Patent 11,884,664 granted on 2024-01-30
US20220251083A1
Chemistry; metallurgy

Protein tyrosine phosphatase inhibitors

 #28 | 2022-07-21
US20220226326A1
Human necessities

HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

 #29 | 2022-04-14 ✅ Patent 11,964,988 granted on 2024-04-23
US20220112214A1
Chemistry; metallurgy

Fused heterocyclic compounds as RET kinase inhibitors

 #30 | 2022-03-24 ✅ Patent 11,813,246 granted on 2023-11-14
US20220087982A1
Human necessities

Pharmaceutical composition

 #31 | 2022-03-17 ✅ Patent 12,180,207 granted on 2024-12-31
US20220081438A1
Chemistry; metallurgy

Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases

 #32 | 2022-02-15 ✅ Patent 11,247,990 granted on 2022-02-15
US16893784
Chemistry; metallurgy

Bicyclic fused pyridine compounds as inhibitors of TAM kinases

 #33 | 2022-02-10 ✅ Patent 12,351,571 granted on 2025-07-08
US20220041579A1
Chemistry; metallurgy

SUBSTITUTED QUINOXALINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES

 #34 | 2021-12-09 ✅ Patent 11,807,651 granted on 2023-11-07
US20210380609A1
Chemistry; metallurgy

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

 #35 | 2021-12-09 ✅ Patent 12,187,721 granted on 2025-01-07
US20210380582A1
Chemistry; metallurgy

Protein tyrosine phosphatase inhibitors

 #36 | 2021-12-09 ✅ Patent 11,932,633 granted on 2024-03-19
US20210380570A1
Chemistry; metallurgy

KRas G12C inhibitors

 #37 | 2021-09-16
US20210284656A9
Chemistry; metallurgy

QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS

 #38 | 2021-09-02
US20210269455A1
Chemistry; metallurgy

QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS

 #39 | 2021-09-02 ✅ Patent 11,267,812 granted on 2022-03-08
US20210269432A1
Chemistry; metallurgy

KRAS G12C inhibitors

 #40 | 2021-07-22
US20210220361A1
Human necessities

SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR

 #41 | 2021-03-18 ✅ Patent 11,571,424 granted on 2023-02-07
US20210077493A1
Human necessities

Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them

 #42 | 2021-01-14
US20210008023A1
Human necessities

N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

 #43 | 2021-01-07 ✅ Patent 11,267,818 granted on 2022-03-08
US20210002287A1
Chemistry; metallurgy

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds

 #44 | 2020-12-31 ✅ Patent 11,414,404 granted on 2022-08-16
US20200407344A1
Chemistry; metallurgy

Compounds for the treatment of BRAF-associated diseases and disorders

 #45 | 2020-12-24 ✅ Patent 11,524,963 granted on 2022-12-13
US20200399279A1
Chemistry; metallurgy

Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors

 #46 | 2020-12-10 ✅ Patent 10,881,652 granted on 2021-01-05
US20200383966A9
Human necessities

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

 #47 | 2020-11-05
US20200345735A1
Human necessities

HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

 #48 | 2020-10-29 ✅ Patent 11,603,374 granted on 2023-03-14
US20200339589A1
Chemistry; metallurgy

Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors

 #49 | 2020-10-29 ✅ Patent 11,472,802 granted on 2022-10-18
US20200339579A1
Chemistry; metallurgy

Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors

 #50 | 2020-10-22 ✅ Patent 11,548,888 granted on 2023-01-10
US20200331911A1
Chemistry; metallurgy

KRas G12C inhibitors

 #51 | 2020-10-08 ✅ Patent 11,634,417 granted on 2023-04-25
US20200317665A1
Chemistry; metallurgy

Protein tyrosine phosphatase inhibitors

 #52 | 2020-10-01 ✅ Patent 11,098,064 granted on 2021-08-24
US20200308194A1
Chemistry; metallurgy

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile

 #53 | 2020-09-17 ✅ Patent 11,028,093 granted on 2021-06-08
US20200291039A1
Chemistry; metallurgy

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

 #54 | 2020-07-23 ✅ Patent 11,376,239 granted on 2022-07-05
US20200230108A1
Human necessities

Pharmaceutical combinations

 #55 | 2020-07-09 ✅ Patent 11,091,486 granted on 2021-08-17
US20200216451A1
Chemistry; metallurgy

Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof

 #56 | 2020-07-09
US20200216416A1
Chemistry; metallurgy

QUINOLINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES

 #57 | 2020-06-04 ✅ Patent 10,729,678 granted on 2020-08-04
US20200171002A1
Human necessities

Preparation of and formulation comprising a MEK inhibitor

 #58 | 2020-03-12 ✅ Patent 11,104,676 granted on 2021-08-31
US20200079770A1
Chemistry; metallurgy

Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases

 #59 | 2020-01-30 ✅ Patent 10,881,652 granted on 2021-01-05
US20200030311A1
Human necessities

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

 #60 | 2020-01-02 ✅ Patent 10,813,936 granted on 2020-10-27
US20200000807A1
Human necessities

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

 #61 | 2019-12-05 ✅ Patent 10,758,542 granted on 2020-09-01
US20190365763A1
Human necessities

Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors

 #62 | 2019-11-28
US20190359597A1
Chemistry; metallurgy

PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

 #63 | 2019-10-03 ✅ Patent 10,766,881 granted on 2020-09-08
US20190300511A1
Chemistry; metallurgy

2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases

 #64 | 2019-09-12
US20190275043A1
Human necessities

SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR

 #65 | 2019-09-05 ✅ Patent 10,889,589 granted on 2021-01-12
US20190270749A1
Chemistry; metallurgy

Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain

 #66 | 2019-09-05 ✅ Patent 10,647,715 granted on 2020-05-12
US20190270743A1
Chemistry; metallurgy

KRas G12C inhibitors

 #67 | 2019-08-29 ✅ Patent 10,584,124 granted on 2020-03-10
US20190263811A1
Chemistry; metallurgy

Crystalline forms

 #68 | 2019-08-22 ✅ Patent 11,504,370 granted on 2022-11-22
US20190255051A1
Human necessities

Treatment of brain cancer

 #69 | 2019-07-18 ✅ Patent 11,214,571 granted on 2022-01-04
US20190218222A1
Chemistry; metallurgy

Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof

 #70 | 2019-07-11 ✅ Patent 10,774,085 granted on 2020-09-15
US20190211017A1
Chemistry; metallurgy

Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds

 #71 | 2019-06-13 ✅ Patent 10,730,880 granted on 2020-08-04
US20190177328A1
Chemistry; metallurgy

4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors

 #72 | 2019-06-06 ✅ Patent 10,590,139 granted on 2020-03-17
US20190169193A1
Chemistry; metallurgy

Method of treatment using substituted imidazo[1,2b]pyridazine compounds

 #73 | 2019-05-30 ✅ Patent 11,174,273 granted on 2021-11-16
US20190161500A1
Chemistry; metallurgy

Quinazoline analogs as receptor tyrosine kinase inhibitors

 #74 | 2019-05-23 ✅ Patent 10,966,985 granted on 2021-04-06
US20190151322A1
Human necessities

Macrocyclic compounds as ROS1 kinase inhibitors

 #75 | 2019-05-16 ✅ Patent 10,689,377 granted on 2020-06-23
US20190144444A1
Chemistry; metallurgy

KRas G12C inhibitors

 #76 | 2019-05-02 ✅ Patent 10,765,678 granted on 2020-09-08
US20190125749A1
Human necessities

Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them

 #77 | 2019-04-11 ✅ Patent 10,745,419 granted on 2020-08-18
US20190106438A1
Chemistry; metallurgy

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

 #78 | 2019-04-11 ✅ Patent 10,485,788 granted on 2019-11-26
US20190105303A1
Human necessities

Pharmaceutical combinations

 #79 | 2019-03-14 ✅ Patent 10,688,100 granted on 2020-06-23
US20190076437A1
Human necessities

Macrocylic compounds as ROS1 kinase inhibitors

 #80 | 2019-02-28 ✅ Patent 10,633,381 granted on 2020-04-28
US20190062330A1
Chemistry; metallurgy

KRas G12C inhibitors

 #81 | 2019-02-21 ✅ Patent 10,561,654 granted on 2020-02-18
US20190054086A1
Human necessities

Pharmaceutical formulations of (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate

 #82 | 2019-01-31 ✅ Patent 10,647,730 granted on 2020-05-12
US20190031684A1
Chemistry; metallurgy

Macrocyclic compounds as TRK kinase inhibitors

 #83 | 2018-11-29
US20180338958A1
Human necessities

METHOD OF TREATMENT USING INHIBITORS OF MITOSIS

 #84 | 2018-11-22 ✅ Patent 10,323,022 granted on 2019-06-18
US20180334450A1
Chemistry; metallurgy

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors

 #85 | 2018-11-22
US20180334441A1
Chemistry; metallurgy

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

 #86 | 2018-10-18 ✅ Patent 10,576,080 granted on 2020-03-03
US20180297985A1
Chemistry; metallurgy

Compounds and compositions as protein kinase inhibitors

 #87 | 2018-10-18 ✅ Patent 10,398,683 granted on 2019-09-03
US20180296533A1
Human necessities

Preparation of and formulation comprising a MEK inhibitor

 #88 | 2018-10-04
US20180282324A1
Chemistry; metallurgy

CRYSTALLINE FORMS OF A PYRROLOPYRIDINE COMPOUND

 #89 | 2018-09-27 ✅ Patent 10,780,073 granted on 2020-09-22
US20180271824A1
Human necessities

N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

 #90 | 2018-09-13
US20180258054A1
Chemistry; metallurgy

PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS

 #91 | 2018-08-09 ✅ Patent 10,548,894 granted on 2020-02-04
US20180221370A1
Human necessities

Combination therapy

 #92 | 2018-07-26 ✅ Patent 10,172,861 granted on 2019-01-08
US20180207162A1
Human necessities

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

 #93 | 2018-07-05 ✅ Patent 10,138,243 granted on 2018-11-27
US20180186791A1
Chemistry; metallurgy

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

 #94 | 2018-07-05 ✅ Patent 10,174,027 granted on 2019-01-08
US20180186790A1
Chemistry; metallurgy

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

 #95 | 2018-06-28 ✅ Patent 10,174,028 granted on 2019-01-08
US20180179203A1
Chemistry; metallurgy

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

 #96 | 2018-06-28 ✅ Patent 10,851,080 granted on 2020-12-01
US20180179182A1
Chemistry; metallurgy

Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds

 #97 | 2018-06-21
US20180169099A1
Human necessities

HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

 #98 | 2018-05-31 ✅ Patent 10,144,734 granted on 2018-12-04
US20180148445A1
Chemistry; metallurgy

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

 #99 | 2018-05-24 ✅ Patent 10,907,215 granted on 2021-02-02
US20180142306A1
Chemistry; metallurgy

Point mutations in TRK inhibitor-resistant cancer and methods relating to the same

 #100 | 2018-05-24 ✅ Patent 10,143,692 granted on 2018-12-04
US20180140603A1
Human necessities

Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them

Also check out Array BioPharma Inc.'s (Boulder, United States) applicant profile with 193 patent applications submitted.

AssigneeID:

4929 ⎘